title: The renal effects of ALK inhibitors.
abstract: Anaplastic lymphoma kinase 1 (ALK-1) is a member of the insulin receptor tyrosine kinase family. In clinical practice, three small molecule inhibitors of ALK-1 are used, namely crizotinib, ceritinib and alectinib. Several more agents are in active pre-clinical and clinical studies. Crizotinib is approved for the treatment of advanced ALK-positive non-small cell lung cancer (NSCLC). According to the package insert and published literature, treatment with crizotinib appears to be associated with kidney failure as well as an increased risk for the development and progression of renal cysts. In addition, this agent is associated with development of peripheral edema and rare electrolyte disorders. This review focuses on the adverse renal effects of Crizotinib in clinical practice.
authors.affiliation: Department of Nephrology, Monceau Park International Clinic Paris, Paris, France. hassan.izzedine@clinique-monceau.com.
authors.forename: Hassan
authors.initials: H
authors.lastname: Izzedine
authors.affiliation: Department of Nephrology, La Rabta Hospital, Tunis, Tunisia.
authors.forename: Rania Kheder
authors.initials: RK
authors.lastname: El-Fekih
authors.affiliation: Department of Nephrology, Yale University School of Medicine, New Haven, CT, 06520, USA.
authors.forename: Mark A
authors.initials: MA
authors.lastname: Perazella
mesh_terms: D000077548:Anaplastic Lymphoma Kinase; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000493:pharmacokinetics; D000077547:Crizotinib; D003560:Cysts / Q000139:chemically induced; D004487:Edema / Q000139:chemically induced; D006801:Humans; D007668:Kidney / Q000187:drug effects* / Q000473:pathology / Q000503:physiopathology; D007674:Kidney Diseases / Q000139:chemically induced / Q000473:pathology / Q000503:physiopathology; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics; D011720:Pyrazoles / Q000009:adverse effects* / Q000493:pharmacokinetics; D011725:Pyridines / Q000009:adverse effects* / Q000493:pharmacokinetics; D020794:Receptor Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib; C000626173:ALK protein, human; D000077548:Anaplastic Lymphoma Kinase; D020794:Receptor Protein-Tyrosine Kinases
keywords: ALK-1; Anaplastic lymphoma kinase; Crizotinib; Cyst; Onco-nephrology; Serum creatinine